Semax Dosage & Protocol Guide: Reconstitution, Cycle Length, and Cognitive Dosing Explained
Semax Peptide
Semax is a synthetic nootropic peptide derived from ACTH (4–10), studied for its effects on cognitive function and neuroprotective pathways. Research suggests Semax influences neurotrophic signaling, including pathways involving BDNF, although its effects are not limited to a single mechanism.
How Semax Works
Neurotrophic Signaling → Neuroplasticity Research → Cognitive + Neuroprotective Research
Semax has been studied for effects on neurotrophic and neuronal signaling, including pathways involving BDNF. These mechanisms are being investigated for their potential roles in neuroplasticity, cognition, and neuroprotection.
Semax is a nootropic peptide, not a hormone or growth peptide.
It is commonly discussed for focus, memory, mental clarity, and stress resilience.
Semax is commonly discussed in shorter research-use cycles. Published human studies have used varying treatment durations, and no universal cycle length or required break has been established.
Morning or early afternoon use is usually preferred to avoid sleep disruption.
Semax Protocol
10 mg vial + 3.0 mL BAC Water → 1 unit = 33.3 mcg → Focus + BDNF Support
Standard Setup
Vial
10 mg
Water
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit = 33.3 mcg
Days 1–3
Starting Phase
Dose300 mcg
Units9 units
Volume0.09 mL
Days 4–7
Build Phase
Dose400–500 mcg
Units12–15 units
Volume0.12–0.15 mL
Days 8–10
Standard Range
Dose500–600 mcg
Units15–18 units
Volume0.15–0.18 mL
Days 11–14
Advanced Range
Dose600–800 mcg
Units18–24 units
Volume0.18–0.24 mL
Protocol Details
FrequencyOnce daily
TimingMorning or early afternoon
Cycle Length5–14 days typical
Optional ExtensionUp to 16 days
Simple Approach
Semax is commonly introduced with lower daily amounts before gradually increasing within a short research-use cycle. Research discussions generally emphasize consistency and individual response rather than progressing automatically to the highest range.
Semax is commonly introduced with lower daily amounts before gradually increasing within a short research-use cycle. Research discussions generally emphasize consistency and individual response rather than progressing automatically to the highest range.
How to Use (Cycle, Timing & Injection)
Most Studied Human RouteIntranasal
Subcutaneous (research-use)Subcutaneous injection
Where (SubQ)Abdomen, thigh, or upper arm
Common TimingMorning or early afternoon
AvoidLate-day dosing
Use StyleShort nootropic cycle
Cycle Structure
Research-Use Cycle5–14 days
Optional ExtensionUp to ~16 days
Commonly Discussed Break1–2+ weeks between cycles
Clinical StandardNo universal cycle or required off-period established
ReasonPrevent receptor adaptation
Timing Notes
Morning use is preferred for focus, clarity, and productivity.
Early afternoon can be used if a second cognitive window is needed.
Avoid late-day dosing due to potential overstimulation and sleep disruption.
Consistency during the cycle improves results.
Track focus, mood, mental energy, and sleep response.
Route Notes
Intranasal administration is the route most represented in published human Semax research.
Other administration routes appear in experimental research, but evidence should not automatically be extrapolated between routes.
Subcutaneous Semax protocols commonly discussed in research settings are not supported by the same level of human clinical evidence as intranasal administration.
Dose, absorption, and effects may differ depending on the administration route.
Reconstitution & Dosing (10 mg Vial)
Vial10 mg
Water3.0 mL bacteriostatic
Concentration3.33 mg/mL
Conversion1 unit = 33.3 mcg
Dose Reference
9 units = 300 mcg
15 units = 500 mcg
18 units = 600 mcg
24 units = 800 mcg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Ensure solution is clear
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C / 36–46°F
Long-term storage: freeze at −20°C / −4°F
Estimated refrigerated shelf life: commonly ~12–24 months when sealed, dry, and protected from light
Estimated frozen shelf life: commonly up to ~2–3 years when stored properly
Keep sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Do not repeatedly freeze and thaw the same vial
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C / 36–46°F
Best used within 30 days
Do not freeze after mixing
Avoid repeated temperature changes
Discard if cloudy, discolored, or if particles appear
Best Practice
Semax should be kept cold and protected from light. Once mixed, label the vial with the date and avoid repeated warming cycles.
Semax should be kept cold and protected from light. Once mixed, label the vial with the date and avoid repeated warming cycles.
Cycle Length & Time Between Cycles
Focus Cycle → Break → Reassess Response → Repeat if Needed
Standard Cycle Structure
Research-Use Cycle5–14 days
Optional ExtensionUp to 16 days
GoalFocus + memory + mental clarity
Time Between Cycles
Commonly Discussed Break1–2 weeks
Helps maintain cognitive responsiveness
Reduces risk of overstimulation or diminishing effect
Gives time to reassess mood, focus, and sleep response
Research-use Framework
The cycle and break shown here are research-use frameworks rather than clinically established requirements. Human Semax studies have used different treatment schedules, including short intranasal courses, so duration should not be interpreted as a standardized Semax regimen.
The cycle and break shown here are research-use frameworks rather than clinically established requirements. Human Semax studies have used different treatment schedules, including short intranasal courses, so duration should not be interpreted as a standardized Semax regimen.
Monitoring During Use
Focus and mental clarity
Memory and learning response
Mood and motivation
Stress resilience
Sleep quality, especially if dosing later in the day
Signs of overstimulation or irritability
Benefits
Studied for effects on cognitive and neuronal signaling
Human research has evaluated effects on brain-network activity and neurologic function
Preclinical research has investigated neuroprotective and memory-related effects
Neurotrophic signaling, including BDNF-related pathways, remains an important area of Semax research
Clinical evidence remains limited compared with established cognitive therapies
Potential Side Effects
Mild headache
Irritability at higher doses
Nasal irritation if used intranasally
Overstimulation if dosed too high
Sleep disruption if taken too late
Long-term safety data remain limited
Stacking Strategies
Cognitive Support → Focus Layer → Stress Balance
Common Pairing Approaches
Focus Stack: Semax + Caffeine + L-Theanine
Nootropic Stack: Semax + Selank
Simple rule
Semax is frequently discussed alongside other cognitive compounds, including Selank. Combination protocols have not been well established in controlled human research, so evidence for each individual compound should not be interpreted as evidence for a specific stack.
Semax is frequently discussed alongside other cognitive compounds, including Selank. Combination protocols have not been well established in controlled human research, so evidence for each individual compound should not be interpreted as evidence for a specific stack.
Important Notes
Semax is a synthetic ACTH (4–10) analog studied primarily in neurologic and cognitive research.
Intranasal administration is the route most represented in published human studies.
Mechanistic research includes neurotrophic signaling and BDNF-related pathways, but Semax should not be reduced to a single mechanism.
No universal human dose, cycle length, or required off-period has been established across indications.
Evidence varies substantially by indication, administration route, dose, and study design.
Long-term human safety data remain limited.
Important Disclaimer
Semax is an investigational peptide and not FDA-approved. This content is for educational purposes only.
Research & References
Primary Research
- Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) Analogue With Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents. Neurochemical Research. 2005.
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of Semax in the Acute Period of Hemispheric Ischemic Stroke (A Clinical and Electrophysiological Study). S.S. Korsakov Journal of Neurology and Psychiatry. 1997.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an Analog of ACTH(4-10) With Cognitive Effects, Regulates BDNF and trkB Expression in the Rat Hippocampus. Brain Research. 2006.
- Shadrina M, Kolomin T, Agapova T, et al. Comparison of the Temporary Dynamics of NGF and BDNF Gene Expression in Rat Hippocampus, Frontal Cortex, and Retina Under Semax Action. Journal of Molecular Neuroscience. 2010.
Research Note: Semax is approved for neurological indications including ischemic stroke in Russia but is not approved by the U.S. FDA. Dosing information reflects protocols used in Russian research and clinical settings; most published human studies originate from Russian institutions, and large multicenter Western clinical trials remain limited.
Comments
Post a Comment